PGCert in Menopause and Andropause
A FHEQ Level 7 Postgraduate Certificate at the integrated interface of perimenopausal physiology, menopause hormone therapy prescribing, the cardiometabolic-bone-cognitive interface, andropause and male hormonal health. 60 UK credits, 30 ECTS, awarded by New Vision University (Tbilisi, Georgia) — UK Campus. Delivered part-time over 30 weeks. £1,995 per delegate.
Last editorial review: 14 May 2026 · Next scheduled refresh: 1 December 2026.
Both hormonal transitions, one PGCert
The menopause is the most under-addressed long-arc transition in UK primary care. The andropause is barely addressed at all. Both share an integrated cardiometabolic, bone, cognitive, and sexual-health phenotype that standard general-practice training does not equip the extended-scope clinician to manage at FHEQ Level 7 depth.
This PGCert is calibrated to that integrated practice. It is anchored to NICE NG23 (November 2024 update), the British Menopause Society HRT Guide (February 2026), NICE TA1143 (fezolinetant — the first non-hormonal vasomotor symptom treatment), the BSSM 2022 testosterone deficiency framework with TRAVERSE 2023 cardiovascular safety nuance, and the joint BMS-RCOG-BSGE-BGCS-FSRH-GIRFT-RCGP 2024 unscheduled bleeding pathway. The Women's Health Strategy 2022 and the NHS England women's-health-hub model provide the service-design backbone for Microcredential 4.
Four 15-credit microcredentials across 30 weeks
Each microcredential is a standalone FHEQ Level 7 / 7.5 ECTS / 150-hour certificate, citable independently.
Menstrual, Perimenopausal & Menopause Physiology and Pharmacology
The HPO axis through the lifespan. Perimenopausal hormonal flux; oestrogen withdrawal and the vasomotor, urogenital, cognitive, sleep, mood, and cardiometabolic symptom domains. Diagnosis without FSH testing per NICE NG23. The pharmacology of oestradiol (oral vs transdermal), progestogens (micronised progesterone vs synthetic), tibolone, and the fezolinetant neurokinin-3 receptor antagonist pathway.
HRT Prescribing & the Cardiometabolic-Bone-Cognitive Interface
The MHT prescribing matrix — uterine status, contraindications, VTE and breast-cancer risk stratification, the timing-of-initiation hypothesis. The cardiometabolic, bone, and cognitive evidence: KEEPS, ELITE, the WHI re-analysis, the 2024 IMS recommendations. Tamoxifen and aromatase-inhibitor co-prescribing in breast-cancer survivors. The BMS-RCOG 2024 unscheduled bleeding pathway. Mid-programme integration milestone at Week 14.
Andropause & Male Hormonal Health
The under-managed male hormonal transition. Late-onset hypogonadism diagnosis per the BSSM 2022 framework; testosterone deficiency phenotypes; replacement options (gel, intramuscular, long-acting); TRAVERSE 2023 cardiovascular safety; PSA monitoring and prostate-cancer risk stratification; fertility considerations. Male sexual dysfunction integrated with the hormonal axis.
Service Design, Audit & the NHS Women's Health Strategy
The women's-health-hub model. Service-design for a primary-care menopause and andropause clinic — referral pathways, audit cycles aligned to QoF/IIF/local ICB priorities, the Capstone preparation. Equality-of-access considerations; the racial and socioeconomic gap in MHT prescribing. Pre-capstone webinar and Synoptic at Week 28.
What an M&A PGCert holder does differently
One illustrative case anchored to current UK and international guidance.
Mrs C, 52, perimenopausal. Vasomotor symptoms (severe night sweats, daytime flushes), sleep disturbance, low mood, vaginal atrophy. Background: oestrogen-receptor-positive breast cancer (treated 2018, on adjuvant tamoxifen until 2024). BMI 28. Bone mineral density T-score −1.8. Family history of premature CHD. Asks about MHT after reading an article.
The integrated M&A decision. A PGCert-credentialled clinician integrates NICE NG23 (MHT is contraindicated in active oestrogen-receptor-positive breast cancer but the patient is now four years off tamoxifen), BMS HRT Guide on breast-cancer survivors, NICE TA1143 (fezolinetant offers a non-hormonal alternative with no breast-cancer-cell stimulation), the 2024 IMS guidance on vaginal oestradiol in breast-cancer survivors (very low systemic absorption; many oncologists now permit it), and the integrated cardiometabolic-bone discussion (HRT for bone protection is not first-line when alternatives exist; bisphosphonate review indicated). The consultation that walks the patient through fezolinetant + topical vaginal oestradiol + bone-health review is the FHEQ Level 7 register in operation.
— Synthesised illustrative case; not a real patient.The unresolved controversy behind the consensus
Approximately 10% of programme content extends into FHEQ Level 8 doctoral-tier reasoning, visually marked as Professor Mode. One illustrative passage:
The Women's Health Initiative (WHI) 2002 publication recast MHT prescribing for two decades. The 2017 and 2022 WHI re-analyses, stratified by age-at-initiation, recovered most of the cardiovascular benefit signal for women aged 50–59 at initiation while preserving the absolute-risk caveats around stroke and VTE in older or oral-only formulations. The "timing-of-initiation hypothesis" — that MHT initiated within ten years of the final menstrual period or before age 60 confers a different risk-benefit profile than MHT initiated later — is now embedded in the IMS, BMS, and Menopause Society recommendations, yet remains an interpretation of observational re-stratification rather than a prospective trial. The KEEPS (lower-dose, transdermal) and ELITE (timing-stratified) trials add supportive evidence but each carries its own limitations. The PGCert-credentialled clinician must hold this controversy in mind when counselling a perimenopausal patient — explaining the timing-of-initiation framework, the residual absolute risks, and the patient's own values regarding symptomatic benefit versus long-term outcome uncertainty. This is the FHEQ Level 8 register: not the application of a guideline, but the negotiation of the limits of the evidence with the patient.
The M&A PGCert evidence anchors
Every clinical assertion is anchored to one of these published authorities.
The microcredential stacking model
Each PGCert is structured as four individually-credentialled microcredentials at FHEQ Level 7. Take one at a time — or stack all four to earn the full Postgraduate Certificate.
The MD Acumen-NVU PGCert architecture mirrors the structured microcredential model now adopted across UK and European higher education — including the University of London microcredential framework. Each of our four 15-credit microcredentials is a standalone certificate at FHEQ Level 7 / 7.5 ECTS / 150 notional learning hours. Completion of all four earns the full 60-credit Postgraduate Certificate qualification, awarded by New Vision University (Tbilisi, Georgia) — UK Campus.
Modular flexibility
Enrol in one microcredential at a time, fitting study around clinical commitments and study-leave budgets.
Lower entry cost
Single microcredential: £550. Full PGCert: £1,995 — a 10% saving on £2,200 sequential.
Standalone certification
Each microcredential is awarded as a separate FHEQ Level 7 / 7.5 ECTS Certificate by NVU UK Campus, citable on CV and portfolio.
PGCert progression
Stack all four microcredentials within five years and complete the Capstone plus Final Synoptic to earn the full 60-credit Postgraduate Certificate.
Two routes to the PGCert.
Route 1 — Sequential microcredentials. Enrol one at a time at £550 each. Capstone and Final Synoptic optional, taken when ready.
Route 2 — Full PGCert from outset. Enrol in all four together at £1,995 (10% saving). Complete Capstone and Final Synoptic at the end of Microcredential 4.
30 weeks part-time, Harvard-mirrored
Four 7-week microcredentials, two integration milestone weeks, and the two-week Capstone-and-Final-Synoptic close.
Five Capstone formats — M&A applications
The 3,000-word Capstone is graded against a published FHEQ Level 7 rubric.
Original research
Example: a single-practice prospective study of fezolinetant uptake and tolerability in MHT-eligible perimenopausal patients with cardiovascular contraindications.
Quality Improvement Project (QIP)
Example: improving the proportion of NICE NG23-eligible patients offered MHT in a typical 8,000-list practice, including the racial and socioeconomic gap audit.
Clinical audit
Example: audit against the BMS-RCOG 2024 unscheduled bleeding pathway — onward referral patterns, time-to-diagnosis, escalation criteria.
Extended case discussion
Example: three linked complex cases — breast-cancer survivor on tamoxifen with severe VMS; POI with autoimmune cluster; perimenopausal patient with type 2 diabetes and dyslipidaemia.
Fifth format — Critical appraisal. A 3,000-word structured critique of a single pivotal trial or framework within the M&A canon (e.g. WHI re-analysis, KEEPS, ELITE, SKYLIGHT/DAYLIGHT for fezolinetant, TRAVERSE 2023). Useful for candidates intending to progress to MSc or doctoral work.
Awarded by, delivered by, and curriculum-aligned with.
The microcredentials and the full PGCert qualification are awarded by New Vision University (Tbilisi, Georgia) — UK Campus. Programme design and delivery is by MD Acumen Ltd as the operating partner.
Curriculum is mapped to, and formal partnership-development conversations are open with: NHS England and the Women's Health Strategy office; the Royal College of General Practitioners (RCGP) via the GPwER framework; the NHSE Centre for Advancing Practice; the Federation of the Royal Colleges of Physicians of the UK; the Royal College of Obstetricians and Gynaecologists (RCOG); the British Menopause Society (BMS); the Faculty of Sexual and Reproductive Healthcare (FSRH); the British Society for Sexual Medicine (BSSM); and local ICB Training Hubs. ECTS conformance is via NVU's institutional accreditation within the European Higher Education Area, mapped to FHEQ Level 7 / EQF Level 7.
Note. "Curriculum-aligned with" describes explicit content mapping to a body's published guidelines. Formal endorsement letters will be sought during the NVU academic-approval phase. This page never claims endorsement that has not been confirmed in writing.
Three ways forward
Try the free M&A Mini-module
A three-hour postgraduate-level taster covering both hormonal transitions. Free. Includes a 15-question Synoptic.
Register interest in Cohort 1
Cohort 1 launches September 2027. Cohort size 30. £1,995 per delegate. Two intakes per year thereafter (March and September).
Commission a cohort
ICB Training Hubs and university partners — open a partnership conversation for cohort commissioning, dedicated audit alignment, or a bespoke intake.
Educational disclaimer. Intended for the continuing professional development of qualified UK healthcare professionals. Does not replace clinical judgement, local prescribing formularies, or specialist advice.
© 2026 MD Acumen Ltd · Registered in England and Wales · 16538952 · Legal & Regulatory Information · enquiry@mdacumen.com